8-K: Aytu BioPharma Reports FY25 Results, Prepares EXXUA Launch

Aytu BioPharma announced its fiscal 2025 full year and fourth quarter results, alongside plans for the commercial launch of EXXUA in the fourth calendar quarter of 2025, targeting the major depressive disorder market.

Summary

• Full year fiscal 2025 net revenue increased 2% to $66.4 million, compared to $65.2 million in fiscal 2024.
• Full year fiscal 2025 net loss improved to $13.6 million, from a net loss of $15.8 million in fiscal 2024.
• Full year fiscal 2025 adjusted EBITDA was $9.2 million, down from $10.8 million in fiscal 2024.
• Cash and cash equivalents stood at $31.0 million as of June 30, 2025, an increase from $18.2 million at March 31, 2025.
• Fourth quarter fiscal 2025 net revenue increased 4% to $15.1 million, compared to $14.6 million in Q4 fiscal 2024.
• Fourth quarter fiscal 2025 net loss significantly worsened to $19.8 million, compared to a net loss of $4.6 million in Q4 fiscal 2024.
• Fourth quarter fiscal 2025 adjusted EBITDA was $2.0 million, consistent with Q4 fiscal 2024.
• The commercial launch of EXXUA, a novel treatment for Major Depressive Disorder (MDD), remains on track for the fourth calendar quarter of 2025, targeting the over $22 billion U.S. prescription MDD market.
• Full year fiscal 2025 net loss included $8.3 million of impairment expense on the Pediatric Portfolio, $2.1 million of restructuring costs related to the Grand Prairie, Texas manufacturing site closure, and $1.7 million of derivative warrant liabilities loss.
• Q4 fiscal 2025 net loss included $8.3 million of impairment expense on the Pediatric Portfolio and $9.9 million of derivative warrant liabilities loss.
• Gross profit percentage decreased to 69% for the full year fiscal 2025 (from 75% in FY24) primarily due to increased cost of sales in ADHD inventory from the now-closed Grand Prairie, Texas manufacturing facility.
• Operating expenses (excluding amortization, restructuring, and impairment) decreased to $39.6 million for the full year fiscal 2025, reflecting continued cost reduction efforts and improved operational efficiencies.
• The Consumer Health business was successfully wound down and divested in the first quarter of fiscal 2025.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company reported a significant Q4 net loss and a decrease in full-year adjusted EBITDA, these were largely influenced by non-recurring items and strategic shifts. The on-track launch of EXXUA into a large market, coupled with overall revenue growth, improved full-year net loss, and demonstrated cost efficiencies, provides a positive outlook for future growth, despite current financial headwinds.

Positives

• Net revenue increased for both the full year (2% to $66.4 million) and the fourth quarter (4% to $15.1 million) of fiscal 2025.
• Full year fiscal 2025 net loss improved to $13.6 million from $15.8 million in the prior year.
• The Pediatric Portfolio net revenue grew significantly, increasing to $2.0 million in Q4 FY25 (from $0.8 million in Q4 FY24) and to $8.8 million for the full year FY25 (from $7.3 million in FY24), driven by a return-to-growth plan.
• Cash and cash equivalents increased substantially to $31.0 million at June 30, 2025, from $18.2 million at March 31, 2025.
• Operating expenses (excluding amortization, restructuring costs, and impairment expense) decreased due to continued cost reduction efforts and improved operational efficiencies.
• The company successfully wound down and divested its Consumer Health business in the first quarter of fiscal 2025.
• The commercial launch of EXXUA, a novel treatment for MDD, remains on track for the fourth calendar quarter of 2025, positioning the company to enter a significant $22+ billion market.
• Aytu reported its 9th consecutive quarter of positive adjusted EBITDA.

Negatives

• Full year fiscal 2025 adjusted EBITDA decreased to $9.2 million from $10.8 million in fiscal 2024.
• Fourth quarter fiscal 2025 net loss significantly worsened to $19.8 million, compared to a net loss of $4.6 million in Q4 fiscal 2024.
• The ADHD Portfolio net revenue slightly decreased for both the full year ($57.6 million vs. $57.8 million) and Q4 ($13.1 million vs. $13.8 million) fiscal 2025, primarily due to a decrease in total prescriptions written.
• Gross profit percentage decreased to 69% for the full year fiscal 2025 (from 75% in FY24) due to increased cost of sales in ADHD inventory resulting from the closure of the Grand Prairie, Texas manufacturing facility.
• The company recorded an $8.3 million impairment expense on its Pediatric Portfolio, primarily due to a shifted commercial focus towards the psychiatric product portfolio and EXXUA launch preparation.
• A derivative warrant liabilities loss of $1.7 million was recognized for the full year fiscal 2025, and $9.9 million for Q4 fiscal 2025, primarily due to an increase in the fair value of liability classified prefunded warrants.
• Restructuring costs of $2.1 million were incurred, primarily related to the closure of the Grand Prairie, Texas manufacturing site.

Risks

• Risks associated with the company’s overall financial and operational performance.
• Potential adverse changes to the company’s financial position or its business, results of operations, strategy, and plans.
• Changes in capital markets and the ability of the company to finance operations in the manner expected.
• Risks relating to gaining market acceptance of its products.
• Risks related to its partners performing their required activities.
• Risks concerning its anticipated future cash position.
• Regulatory and compliance challenges.
• Future events under current and potential future collaborations.

Future Outlook

Aytu BioPharma anticipates a significant transformation into an industry leader in complex CNS diseases, with EXXUA serving as a major growth catalyst. The company expects to exit fiscal 2026 on a trajectory that positions it as one of the fastest-growing CNS-focused companies in the industry, realizing the significant market potential of EXXUA. Discussions are also underway to expand EXXUA's existing intellectual property through various potential life cycle management approaches.

Management Comments

• "We enter fiscal 2026 with an opportunity to significantly transform Aytu into one of the industry leaders in addressing complex CNS diseases following our recent exclusive agreement to commercialize EXXUA for major depressive disorder."
• "EXXUA is a perfect strategic fit and will be a centerpiece of Aytu’s commercial efforts going forward considering the significant commercial potential, uniqueness of the product, our sales force’s CNS focus and alignment with our proprietary Aytu RxConnect patient access platform."
• "We remain on track to launch EXXUA in the fourth quarter of calendar 2025."
• "The results of the fourth quarter and fiscal year highlight the stability within our existing ADHD and Pediatric portfolios as well as our focus on driving efficiencies across our operations to report our 9th consecutive quarter of positive adjusted EBITDA."
• "As we ramp up our commercial focus on EXXUA, it is our expectation that we will exit fiscal 2026 on a trajectory that positions Aytu as one of the fastest growing CNS-focused companies in the industry."
• "We look forward to the realization of the significant market potential of EXXUA while positively impacting the lives of MDD patients."

Industry Context

Aytu BioPharma is strategically pivoting its commercial efforts towards complex central nervous system diseases, with the upcoming launch of EXXUA positioning the company to enter the substantial over $22 billion United States prescription Major Depressive Disorder (MDD) market. EXXUA is described as a novel first-in-class oral selective serotonin 5HT1a receptor agonist, indicating an attempt to differentiate within a competitive therapeutic area.

Stakeholder Impact

• Shareholders: Potential for future value creation from the EXXUA launch, but current financial performance includes significant Q4 losses and dilution from warrant liabilities. The increase in cash provides some stability.
• Patients: The introduction of EXXUA offers a novel treatment option for adults with Major Depressive Disorder, aiming to improve their quality of life.
• Employees: Restructuring costs and the closure of the Grand Prairie manufacturing facility indicate workforce adjustments and operational streamlining.
• Customers (Physicians/Pharmacies): Continued availability of ADHD and Pediatric portfolios, with the addition of a new MDD treatment option (EXXUA).
• Creditors: The increase in cash and continued positive adjusted EBITDA provide some reassurance, though the overall net loss remains a concern.

Next Steps

• Launch EXXUA commercially in the fourth calendar quarter of 2025.
• Finalize EXXUA product manufacturing, labeling, serialization, and delivery to the third-party logistics provider.
• Continue key opinion leader engagement for EXXUA.
• Refine sales territory alignment and physician targeting for EXXUA.
• Prepare promotional materials and refine physician messaging for EXXUA.
• Conduct commercial and government payor assessment for EXXUA.
• Engage in discussions to expand upon the existing intellectual property for EXXUA through various potential life cycle management approaches.
• Liquidate higher-cost ADHD inventory in the coming quarters to normalize ADHD gross profit percentage.
• Exit fiscal 2026 on a trajectory that positions Aytu as one of the fastest-growing CNS-focused companies in the industry.

Key Dates

Recommendation

While Aytu BioPharma is making a significant strategic pivot with the on-track launch of EXXUA into a large and growing market, which presents substantial future growth potential, the current financial results are mixed. The improved full-year net loss is positive, but the substantial Q4 net loss, the decrease in full-year adjusted EBITDA, and the impact of derivative warrant liabilities introduce considerable near-term uncertainty and execution risk. A 'hold' recommendation allows investors to observe the initial commercial performance of EXXUA and the company's ability to translate its strategic initiatives into sustained financial improvement before making a more definitive investment decision.

Keywords

Aytu BioPharma, AYTU, financial results, Q4 2025, FY 2025, EXXUA, major depressive disorder, MDD, ADHD, Adzenys XR-ODT, Cotempla XR-ODT, pharmaceutical, CNS diseases, drug launch, FDA approval, earnings, biopharma